Biological
Adjuvanted RSVPreF3 vaccine
Adjuvanted RSVPreF3 vaccine is a biological therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Not yet recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
not_yet_recruiting150%
active_not_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07092865
not_yet_recruitingphase_2
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
NCT07712380
Clinical Trials (2)
Showing 2 of 2 trials
NCT07092865Phase 2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07712380Phase 2
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2